Increased Ankyrin Repeat Domain 1 (ANKRD1) levels linked to gain of function mutations have been associated to total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans. The link between increased ANKRD1 level and cardiac structural and functional disease is not understood. To get insight into this problem, we have generated a gain of function ANKRD1 mouse model by overexpressing ANKRD1 in the myocardium.
Methods and results
Ankrd1 is expressed non-homogeneously in the embryonic myocardium, with a dynamic nucleo-sarcomeric localization in developing cardiomyocytes. ANKRD1 transgenic mice present sinus venosus defect, which originates during development by impaired remodelling of early embryonic heart. Adult transgenic hearts develop diastolic dysfunction with preserved ejection fraction, which progressively evolves into heart failure, as shown histologically and haemodynamically. Transgenic cardiomyocyte structure, sarcomeric assembly, and stability are progressively impaired from embryonic to adult life. Postnatal transgenic myofibrils also present characteristic functional alterations: impaired compliance at neonatal stage and impaired lusitropism in adult hearts. Altogether, our combined analyses suggest that impaired embryonic remodelling and adult heart dysfunction in ANKRD1 transgenic mice present a common ground of initial cardiomyocyte defects, which are exacerbated postnatally. Molecular analysis showed transient activation of GATA4-Nkx2.5 transcription in early transgenic embryos and subsequent dynamic transcriptional modulation within titin gene.
. Conclusions
ANKRD1 is a fine mediator of cardiomyocyte response to haemodynamic load in the developing and adult heart. Increased ANKRD1 levels are sufficient to initiate an altered cellular phenotype, which is progressively exacerbated into a pathological organ response by the high ventricular workload during postnatal life. Our study defines for the first time a unifying picture for ANKRD1 role in heart development and disease and provides the first mechanistic link between ANKRD1 overexpression and cardiac disease onset.
Introduction
Ankyrin Repeat Domain 1 (ANKRD1, also known as Cardiac Ankyrin Repeat Protein, CARP) is a member of the muscle-specific ankyrin repeat proteins (MARP) family, which also includes ANKRD2/Arpp and DARP. 1, 2 MARP proteins are involved in muscle stress response and are structurally characterized by four ankirin repeats, a coiled-coil domain, a nuclear localization signal, and a PEST degradation sequence, which mediates its rapid turnover via the ubiquitin-proteasome pathway. 3, 4 ANKRD1 is highly expressed during heart development and downregulated in adult life. [5] [6] [7] In the developing heart, ANKRD1 has been proposed to work as transcriptional cofactor and negative regulator of myocardial gene expression. [5] [6] [7] ANKRD1 is a target of Nkx2.5 in vivo 5 and its promoter can be cooperatively activated by Nkx2.5 and GATA4. 6 In adult cardiomyocytes, ANKRD1 is normally located at the sarcomere, but it has been shown to translocate to the nucleus upon mechanical stimulation in vitro. 2 In the sarcomere, ANKRD1 is found at the I-band where it is a component of titin N2A-linked signalling complex. 2, 8 Physical interaction between ANKRD1 and titin N2A spring domain has been shown to reduce PKA phosphorylation and titin compliance. 1 ANKRD1 has additionally been shown to functionally interact with GATA4 in the I band and the nucleus, thereby modulating GATA4-mediated sarcomeric gene expression and sarcomeric organization. 9, 10 Interactions with several additional partners involved in modulation of muscle structure and function have been reported. 3, 8 ANKRD1 is therefore part of a stretch-sensing unit capable of relaying biomechanical stress signals to the regulation of gene expression. In line, ANKRD1 expression is up-regulated in response to hypertrophy and in heart failure (HF). 6, [11] [12] [13] However, the absence of cardiac phenotype in ANKRD1 knock-out mouse models, 10, 14 combined with contradictory results from loss and gain of function approaches, 3, 9, 15, 16 have precluded a clear understanding of ANKRD1 role in adult heart. 
Genetic mutations in ANKRD1, mostly associated to a gain of function condition, have been correlated to several types of cardiac disease in humans. ANKRD1 missense mutations have been identified in patients with hypertrophic and dilated cardiomyopathy (HCM, DCM). [17] [18] [19] ANKRD1 has additionally been identified as a candidate gene for total anomalous pulmonary venous return (TAPVR) in isolated patients. 20, 21 TAPVR is a congenital heart disease (CHD) which affects 1:15 000 live births and is characterized by incorrect pulmonary vein (PV) drainage into the heart. 22 TAPVR leads to high mortality rate in the first year of life, unless surgically corrected. Reported TAPVR patients presented either chromosomal rearrangement or T116M-ANKRD1 mutation, leading respectively to a three-to four-fold increase in ANKRD1 transcript levels or 10-20% increase in protein stability, 4, 21 suggesting that ANKRD1 expression levels must be tightly regulated during embryogenesis.
Here, we show that Ankrd1 is heterogeneously expressed in the developing heart, with a dynamic nucleo-sacroplasmic sublocalization. Myocardial-overexpressing ANKRD1 transgenic (Tg) mice are born with congenital sinus venosus (SV) defect. In postnatal life, diastolic dysfunction and progressive transition from adaptive to maladaptive response occurs. Increased ANKRD1 levels are sufficient to initiate an altered cellular phenotype in the embryonic heart, which is exacerbated postnatally by high ventricular workload.
Methods

Mouse lines
Human wt-ANKRD1-FLAG tagged cDNA 4 was cloned downstream of the 5 kb Myh6 promoter. 23 Two Tg lines were generated by pronuclear microinjection of linearized constructs into FVB oocytes. Transgene expression was characterized by western blotting and immunofluorescence (Supplementary material online, Figure S1 ). Genomic DNA was PCR-genotyped from tails of anaesthetized mice (Zoletil, 30 mg/kg, i.p) or the amniotic sac of embryos isolated after sacrifice by cervical dislocation of the anaesthetized mother. Isolated embryos, neonatal, and adult hearts were isolated and processed using standard procedures for subsequent histological, biochemical, or molecular analysis. Animal procedures used conformed to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
PCR analysis
RNA isolation, cDNA transcription, and quantitative PCR were conducted using standard procedures. Primers for titin PCR amplification were selected to avoid regions with repetitive nucleotide sequences and potential incorrect priming. All primer sequences are available in Supplementary material online, Table S1.
Isolated myofibril analysis
Myofibrils were prepared by homogenization of permeabilized strips of frozen ventricular tissue in relaxing solution on ice. 24 Mechanical measurements from myofibrils in isometric conditions were performed during activation-relaxation cycles achieved by fast solution switching. 25 SL-resting tension relations were determined as previously described. 26 
Echocardiographic analysis
Transthoracic echocardiography was performed using a high-resolution echo machine with a 30 Mhz probe (VEVO 2100 Visualsonics). Both males and females mice were analysed. Mice were chest shaved and anaesthetized with 3% isoflurane, and temperature controlled anaesthesia was maintained with 1.5% isoflurane. Two-dimensional cine loops and M-mode cine loops of a long-axis view and a short-axis view of the left ventricle (LV) were recorded. Interventricular septum thickness, left ventricular internal diameter, and left ventricular posterior wall thickness were measured in diastole and systole from M-mode long-axis view. Ejection fraction (EF) and fractional shortening (FS) were automatically calculated by the machine software. 
Doppler analysis of left ventricular and PV flow
Statistical analysis
Data are presented as mean ± standard deviation. Comparisons between groups were performed by Students unpaired t-test, Mann-Wilcoxon W test, or Wilcoxon signed-rank test where appropriate, based on experimental design. P < 0.05 was considered statistically significant.
Detailed methods are available in Supplementary data online.
Results
Ankrd1 is heterogeneously expressed in the developing myocardium
We initially examined Ankrd1 expression in embryonic hearts. In situ hybridization (ISH) on sections showed that Ankrd1 mRNA is expressed in the myocardium from E7.5 onwards, although not homogeneously ( Figure 1A) .
At the venous pole of the heart, at E10.0 differential Ankrd1 mRNA levels were observed at the left and right pulmonary ridge and the sinus horns (white arrows, Figure 1Bb ). By E10.5, heterogeneous mRNA staining was visible also within the developing septum primum (black arrow, Figure 1Bd ), around the PV (white arrowhead, Figure 1Bd ) and systemic veins entrance (red arrowheads, Figure 1Ac and Bd). This expression profile was maintained at E12.5 (Figure 1Ad and 1Be, f) and E14.5 (Figure 1Bg , h).
Heterogeneous Ankrd1 mRNA expression was detected also within the compact and trabecular layers of the left and right atrial chambers (LA, RA) (green arrows, Figure 1Cb , e), and the atrioventricular canal (red asterisk, Figure 1Bh and Ce). Stronger Ankrd1 expression was visible in the outflow tract and the right ventricle ( Figure 1Ac -e), whereas weaker and more heterogeneous expression was detected in the LV and the interventricular septum (yellow arrows, Figure 1Ac, d and Cd, f
Antibody staining confirmed heterogeneous Ankrd1 protein expression in developing cardiomyocytes ( Figure 1D) . Subcellular protein localization was always detected at the sarcomeric I band ( Figure 1E) ; additional nuclear localization was frequently observed in E10.5 cardiomyocytes (Figure 1Ea , b) but was no more detectable by E14.5 (Figure 1Ec, d ).
ANKRD1 finely modulates rotation and remodelling in the early myocardium
We next aimed to assess the effects of a genetically-based increase in ANKRD1 levels on cardiac structure and functionality. Thus, we generated two transgenic (Tg) mouse lines overexpressing human ANKRD1 
in the myocardium under Myh6 gene promoter (Supplementary material online, Figure S1A ), which is active from E7.5 onwards. 27 Transgene protein levels were very modest in E10.5 and E14.5 embryos (Supplementary material online, Figure S1A and B and not shown), but increased, to a similar order of magnitude, in neonatal and 10M Tg hearts (Supplementary material online, Figure S1A ). ANKRD1 transgene presented always a sarcomeric sub-localization, however, some nuclear signal was additionally visible in adult Tg hearts (Supplementary material online, Figure S1C ). Preliminary analysis did not reveal phenotypic differences between the two Tg lines (not shown), thus detailed analysis was performed on a single line.
We initially investigated early cardiac development. E10.5 Tg hearts presented well-developed atrial and ventricular chambers, which however appeared more compressed along the cranio-caudal and dorsoventral axes, were laterally displaced and presented a reduced rotational angle if compared to wt littermates (Figure 2Aa , e). In particular, the sinoatrial region was more caudally oriented in Tg hearts, similarly to E9.5 wt embryos ( Figure 2Be) . Compressed shape and malrotation affected both internal remodelling and the relative orientation between sino-atrial myocardium, the flanking dorsal mesocardium, and the proepicardium (Figure 2Aa , e). This resulted in malpositioning of the developing septum primum, of the pulmonary ridges, as well as of the sinus horns myocardium, visualized by Tbx18 expression 28 (Figure 2Ac , d, g, h). The sinus horns confluence, which defines the entrance of the cardinal veins into the sino-atrial region, and the pulmonary pit, delineating the route of canalization of the PV, were distinct in Tg hearts as in wt embryos. However, in Tg hearts, a mesh of Tbx18 þ mesenchyme was additionally detected within the dorsal mesocardium. Tbx18 þ mesenchyme was more abundant caudally, in proximity of the differentiating sinus horns myocardium (Figure 2Ba In conclusion, E10.5 Tg hearts, although apparently progressed in development, are 'cast' into a more immature topological arrangement that strongly affects venous pole remodelling.
ANKRD1 Tg hearts present SV defects
By mid-foetal stages, most Tg hearts presented a misshapen sino-atrial region. Three-dimensional anatomically-based reconstruction outlined 
the malpositioning of venous inlets, which however drained in the correct atrial chamber ( Figure 3A) . Additionally, Tg hearts presented a network of microcanalizations, delineating a fine network of ectopic connections between the PV and systemic veins, which partially drained into the vestibular region through small fenestrations ( Figure 3Ad , f and Supplementary material online, Figure S3 ). These anomalous veno-atrial connections have been associated to SV defects in humans. 29 Anomalous veno-atrial connections were normally accompanied (20/27 embryos) by atrioventricular rotational defects and compressed appearance of the vestibular region (Figure 3Ad and Supplementary material online, Figure S3 ). However, in a minority of Tg embryos (7/27) SV defects occurred in the absence of morphogenetic impairment (not shown), thus indicating higher venous pole sensitivity to increased ANKRD1 expression.
At the early postnatal life, only subtle differences could be detected between wt and Tg hearts by external anatomical observation (Figure 3Ba, e ), however, SV defects could be clearly outlined histologically ( Figure 3Bb -d, f-h). A misshapen fossa ovalis was also clearly recognizable ( Figure 3Bg) .
In conclusion, ANKRD1 Tg hearts present SV defects. Fine alterations in cardiac venous pole remodelling impact both systemic and PV development, which are closely interwined. 30 Our data support the hypothesis that SV defects are likely originated by impaired remodelling of the sino-atrial myocardium during embryonic development.
To investigate the mechanisms for SV defects, we initially wondered whether master transcription factors GATA4 and Nkx2.5, functionally associated to ANKRD1, could be transcriptionally affected in early Tg embryos. qPCR analysis showed that GATA4 and Nkx2.5 mRNA levels were increased in E10.5 Tg hearts (P < 0.05 for Nkx2.5), however, this difference was blunted at E14.5 ( Figure 4A) . These results indicate that very low ANKRD1 overexpression is sufficient to affect GATA4 and Nkx2.5 transcription, however, exclusively within the short time window of ANKRD1 nuclear localization. Thus, GATA4-Nkx2.5 transcriptional modulation could be involved in SV defects onset.
As cardiac remodelling occurs thought the entire foetal period, these results raise the possibility that additional ANKRD1-mediated mechanisms should account for phenotype progression in Tg hearts, including altered chamber morphology. ISH analysis of E14.5 Tg hearts did not show differences in regional distribution of genes which delineate and/or define myocardial landmarks and compartments, such as Pitx2 (left-right identity), 31 Tbx3 (primary myocardium), 32 Nppa, Gja5 (chamber myocardium), 32, 33 Mlc2v (ventricular myocardium), 33 Bmp10 (trabecular 
myocardium), 34 and Tbx18 (SH myocardium) 28 (Figure 4B ), thus ruling out late transcriptional effects on myocardial patterning.
Adult ANKRD1 Tg mice develop progressive ventricular diastolic dysfunction
We next investigated the consequences of ANKRD1 overexpression in adult life. Tg mice were born according to Mendelian ratio, however by 10 months (10M) they presented a reduced viability (88, 5%Tg vs. 96, 9%wt; P < 0.05). Histological analysis uncovered a severely dilated left atrium in all Tg hearts ( Figure 5A) . LA thrombi, patent foramen ovale (PFO), ventricular dilatation, and altered chamber geometry could additionally be detected as isolated or combined defects ( Figure 5A) . Moderate fibrosis was detected in ventricular (Figure 5Am, n) , but not atrial chambers, except for the organized thrombi (Figure 5Ag, h) .
Accordingly, TGFb levels and TGFb-activated ERK1/2 phosphorylation 35 were moderately increased in Tg hearts (Supplementary material online, Figure S4) .
We compared wt and Tg cardiac function by echocardiography and haemodynamic analysis at 2M and 10M ( Table 1) . Echocardiography indicated preserved LV systolic function (i.e. EF and FS values) in 2 and 10M Tg mice, and absence of ventricular hypertrophy at 10M. However, transmitralic flow analysis in 2M mice revealed comparable E/A ratio but higher DT values in Tg animals, suggesting an initial diastolic dysfunction. By 10M, remarkably increased E/A ratio and reduced DT value were found in Tg mice, indicating progression of diastolic dysfunction with aging. Remarkably increased MPI 36 in 10M Tg vs. wt mice supports this notion.
PV flow analysis revealed the presence of a small late diastolic wave (d2) in 2M Tg mice (6/8) ( Figure 5B) , indicating additional blood inflow into the left atrium, presumably via the identified cavo-pulmonary shunts 
( Figure 3B and Figure 5A ). We hypothesize that cavo-pulmonary shunts became haemodynamically significant only in late diastole due to onset of a temporary pressure gradient which favours the R to L shunt. The d2 wave was no longer detected in 10M Tg, indicating a change in L/R atrial chamber pressure gradients with age.
At 2M, a wave value was significantly higher in Tg than wt mice, indicating more effective atrial contraction ( Table 1 and Figure 5B ). s and d wave values were also higher in Tg than wt mice ( Table 1 and Figure 5B ), indicating ventricular systolic compensation according to Frank Starling law. Comparable a/d ratio indicated similar haemodynamics in 2M wt vs. Tg mice during atrial systole and ventricular diastole; however, s/d ratio was <1 in 2M Tg mice, as it occurs in early diastolic dysfunction. 37 By 10M, decreased a and s values, as well as s/d and a/d ratio indicated less effective atrial contraction and very different haemodynamics in Tg vs. wt mice, underlying a severe diastolic dysfunction and loss in LA contractility. Doppler visualization confirmed this latter finding. Visual assessment of mitral valve flow did not reveal anomalies in valve functionality, thus ruling out valvular impairment as the leading cause for diastolic dysfunction.
Overall, functional analysis indicates that 2M Tg mice present initial ventricular diastolic dysfunction accompanied by increased atrial contractility; by 10M, diastolic dysfunction progresses into diastolic HF, associated to LA enlargement and loss of LA contractility. In line, cardiac disease marker BNP was also significantly increased in 10M Tg hearts (Figure 5Ao) .
Atrial dilatation and diastolic HF together can lead to pulmonary oedema, whereas diastolic HF can occasionally lead to ventricular fibrillation. Thrombi formation in 10M Tg mice indicates altered atrial haemodynamics, possibly caused by HF and/or PFO defects. 38 All these comorbidities can have a fatal outcome, therefore they likely account, as single or combined events, for the reduced viability in 10M Tg mice.
Cardiomyocyte contractility is impaired in ANKRD1 Tg hearts
We tested the hypothesis that impaired cardiomyocyte contractility could contribute to CHD and adult diastolic dysfunction in Tg hearts. Isolated myofibrils from mid-foetal, early postnatal, and 10M hearts were tested for passive tension. Neonatal and 10M myofibrils were additionally tested for active mechanical properties.
Sarcomere length-resting tension (SL-RT) relations (i.e. passive mechanical properties) of wt and Tg myofibrils were comparable at E14.5 
( Figure 6Aa ) and 10M (Figure 6Ac ), but not in newborns (Figure 6Ab) . Interestingly, neonatal wt myofibrils retained passive properties of foetal stage, as expected, 39 whereas Tg myofibrils presented a functional shift towards the stiffer phenotype of adult wt (Figure 6Ab, c) .
Regarding active mechanical properties (Figure 6Ad) , the maximally calcium activated isometric force value (P 0 ) was significantly higher in neonatal Tg than wt myofibrils, and comparable to adult wt value. Kinetics of force rise (k ACT ) and relaxation (slow and fast k REL ) and tension relaxation parameters (D slow ) were comparable in neonatal Tg and wt myofibrils. Interestingly, adult wt and Tg myofibrils showed comparable k ACT , while force relaxation was clearly impaired in Tg, as shown by significantly increased D slow and decreased fast k REL . Thus, Tg myofibrils present a differential modulation of passive and active contractile properties during life time, i.e. reduced compliance at neonatal stage and overall slowed down relaxation at 10M.
We investigated the molecular basis for early functional changes observed in Tg myofibrils. Regulation of passive mechanical properties is mainly due to modulation of titin compliance either posttranscriptionally, or at the transcriptional level via alternative splicing. 40, 41 Here, we tested the hypothesis that titin transcription could be affected in ANKRD1 Tg hearts. Titin splicing regulation involves N2B/N2BA isoforms ratio modulation and N2BA length modification via exons inclusion at the middle Ig and PEVK spring regions. 40, 41 In E14.5 Tg hearts, the transcripts levels of titin did not show significant differences, similar to representative thick, thin and Z band components ( Figure 6B) . The N2B/N2BA isoform ratio was slightly, though not significantly, increased ( Figure 6C) . In neonatal Tg hearts, expression of analysed transcripts were unchanged ( Figure 6B) . However, N2B/N2BA ratio was now clearly modified and significantly reduced in Tg samples ( Figure 6C) , indicating a transcriptional shift towards the more compliant N2BA isoform. This result was somehow surprising, since functional data indicated a reduced compliance in neonatal Tg myofibrils (Figure 6Ab) . Intriguingly, when we performed PCR scanning analysis of N2BA exon usage within middle Ig and PEVK regions, we found that Tg hearts used a different exon combination, leading to expression of shorter, therefore less compliant, N2BA titin isoforms ( Figure 6C and Supplementary material online, Figure S5 ). Thus, a wide modulation within titin gene transcription accompanies the biomechanical changes of neonatal Tg myofibrils.
Cardiomyocyte organization and ultrastructure are progressively impaired in ANKRD1 Tg mice
Having established that ANKRD1 overexpression impairs sarcomeric function, we next explored the impact of these alterations on cellular organization. Cardiomyocyte disorganization was visible in Tg hearts from E10.5 onwards ( Figure 7A) . Confocal analysis showed that E14.5 Tg cardiomyocytes were mostly distorted and presented sarcomeric disaligment (Figure 7Ai , l, Supplementary material online, Videos S1 and S2). Electron microscopy analysis of neonatal Tg ventricles confirmed sarcomeric disorganization and additionally showed focal areas of myofibrillar disruption (Figure 7Bf, i) . Swollen mitochondria with abnormal cristae (Figure 7Bi ) and rare lipid droplets in the cytoplasm (Figure 7Bf) were also found. By 10M, ultrastructural disorganization progressed in Tg ventricles, as indicated by the increased myofibril loss, mitochondrial damage 
and accumulation of lipid droplets. Myofibrillar loss was not detected in adult Tg LA (Figure 7) .
In conclusion, tight regulation of ANKRD1 expression is required for proper modulation of cardiomyocyte structure and of sarcomeric assembly and stability, from early development to adult life. Impaired embryonic remodelling and contractility in ANKRD1 Tg mice are therefore underlined by a common cellular basis.
Discussion
Here, we have presented the first longitudinal study aiming to assess the consequences of ANKRD1 myocardial overexpression from development to adult stage. Novel findings of our study are: (i) the presence of SV defects in ANKRD1 Tg mice. To our knowledge, this is the first mouse model for such CHD. (ii) The pathological phenotype of adult ANKRD1 Tg hearts in the absence of pharmacological stimuli or pressure overload. This feature has not been highlighted before, 16 possibly because of late appearance of gross cardiac abnormalities. The mechanistic link between ANKRD1 overexpression, CHD and adult cardiomyopathy are hereafter discussed, in relation to ANKRD1 expression and subcellular localization.
ANKRD1 expression and overexpression
We have here shown a discrete sub-compartmentalization of Ankrd1 expression and dynamic nucleo-sarcomeric localization in the developing heart, not recognized in previous studies. 5, 7 The limited time window of nuclear localization suggests that ANKRD1 can sense ongoing haemodynamic changes 42 and respond by fine tuning its interacting partners ( Figure 8A) .
Extreme sensitivity to increased ANKRD1 levels in Tg hearts is therefore not surprising. Very low levels of Tg expression in E10.5 Tg hearts were sufficient for morphological and cellular phenotype onset and for 
transient GATA4 and Nkx2.5 transcriptional up-regulation. ANKRD1 expression can in turn be regulated by Nkx2.5 and GATA4 5, 6, 9 Thus, our data suggest a novel in vivo autoregulatory loop for increased GATA4 and Nkx2.5 transcription, mediated by ANKRD1 binding. We cannot rule out that GATA4 could be directly involved in Nkx2.5 transcriptional activation. 43 GATA4-ANKRD1 functional interaction can lead to increased GATA4-mediated sarcomeric gene expression and has been proposed to contribute to sarcomere homeostasis. 9, 10 On the other hand, GATA4 and Nkx2.5 together can co-activate target genes regulating cardiac development. 44 We propose that ANKRD1-mediated GATA4 and Nkx2.5 transcriptional modulation contributes both to cellular phenotype onset and to early abnormal venous pole remodelling, leading to SV defects ( Figure 8B) .
The extreme sensitivity to ANKRD1 levels in our Tg mice is in line with TAPVR occurrence in patients presenting a mild increase in ANKRD1 transcripts and/or protein stability. 4, 21 TAPVR and SV defects present a common feature, i.e. abnormal pulmonary venous connections: PV are not connected to the left atrium in TAPVR, whereas partial anomalous PV connections characterize SV defects. 45 Our data support the hypothesis that both diseases can stem from a common developmental defect, i.e. reduced cardiac venous pole remodelling. 30, 45 The limited time-window of GATA4-Nkx2.5 transcriptional modulation cannot account for the full, complex phenotypic spectrum of Tg mice. Dynamic titin isoform alterations in Tg hearts and reduced myofibrillar compliance accompanied by increased max force in neonatal Tg myofibrils 1, 46, 47 (Figure 8B-D) , altogether indicate a correlation between increased ANKRD1 levels and titin response. Transgene expression was exclusively sarcomeric in foetal and neonatal hearts, suggesting that altered ANKRD1 stoichiometry could directly affect titin mechanosensing properties at these stages. However, as titin compliance can be finely modulated by ANKRD1 binding, 1,48 its mechanosensing properties could be affected already in early Tg embryos. We cannot additionally 
rule out that ANKRD1-GATA4(-Nkx2.5)-mediated cardiomyocyte disorganization can contribute to trigger an initial titin response ( Figure 8B) . Titin can finely respond to changes in sarcomere stretch by differential splicing of its spring elements, resulting in either increased or decreased passive stiffness 40, 49 and can additionally regulate sarcomere assembly 50 and stability 41 from development to adult life. 40, 49, 51 Thus, our data suggest that titin-mediated mechanotransduction impairment plays a relevant role in Tg cardiomyocyte phenotype functional modulation ( Figure 8B) .
Altogether, our results show that activation of GATA4-Nkx2.5 transcription and titin gene modulation are temporally distinct but integrated systems of rapid response to changes in ANKRD1 levels and in haemodynamic load.
ANKRD1 overexpression and cardiac functional disease
Early postnatal transgenic cardiomyocytes presented signs (functional, molecular, and ultrastructural changes) of ongoing cardiac disease. They are likely the result of mechanotransduction impairment, due to changes in haemodynamic load and increased Tg expression at birth.
Disease progression in postnatal life is triggered by both the cellular/ functional and the anatomical substrates. 2M Tg hearts presented an early adaptive response, likely triggered by small volume overload due to the R-L shunt and impaired compliance of ventricular cardiomyocytes ( Figure 8C) . Progressively, altered haemodynamics and impaired functionality in Tg cardiomyocytes initiate a vicious loop, that peaks to the maladaptive organ response observed at 10M ( Figure 8B) . Dramatic worsening of Tg ventricular cardiomyocyte ultrastructure in adult hearts could be caused by their altered mechanosensing properties combined to the high workload of ventricular chambers. As a support to our hypothesis, myofibrillar loss was absent in adult Tg LA, in line with its major function as a reservoir chamber.
Functional analysis demonstrated a significant slowing down in the fast component of myofibrillar relaxation kinetics in 10M Tg hearts. This finding indicates an impairment in inter-sarcomeric dynamics, likely due to the altered load conditions. 52 Comparable passive properties of 10M wt and Tg indicated that late diastolic dysfunction is due to impaired ventricular relaxation (lusitropy), not impaired passive stiffness ( Figure 8D) . Additional possible contributors to cardiomyocyte dysfunction, such as altered intracellular Ca 2þ dynamics and impaired energetic costs 53, 54 most likely contribute to the diastolic impairment.
The mechanistic links between ANKRD1 overexpression and cardiac disease progression can only partially be elucidated. However, transgene nucleo-sarcomeric sublocalization during postnatal life indicates that ANKRD1 can sense the altered cardiomyocyte status and, once a certain threshold is reached, can respond by modulating its interacting partners.
ANKRD1 gain of function mutations have been identified in HCM and DCM patients. 18, 19 DCM-associated features are ventricular dilatation, wall thinning, and reduced systolic function, whereas HCM presents with normal or increased systolic function and strong variability: a subset of patients develop HF, a minority further progresses to end stage HF, which resembles DCM. 55 At the organ level, ANKRD1 Tg hearts present typical features of HCM, i.e. diastolic dysfunction with preserved systolic functionality and phenotypic variability associated to disease progression. 56 Hypertrophic response, the hallmark of human HCM disease, was not present in ANKRD1 Tg mice, however, this is a shared characteristic of Tg mouse models of sarcomere-associated HCM mutations. 57, 58 Contractile dysfunction plays a central role in cardiomyopathies onset and progression. Increased contraction is associated to HCM onset, whereas disruption of sarcomeric function and/or structure has been suggested as early landmark of DCM. 55 ANKRD1 Tg neonatal hearts presented both features, i.e. increased myofibrils maximal force and an initial sarcomeric loss ( Figure 8C and D) . Cardiac disease progression is characterized by increased cardiomyocyte compliance, which is generally higher in DCM and end-stage HF, compared to early-stage patients. 59, 60 In this line, the dynamic alteration of contractile properties in Tg myofibrils parallels functional changes observed in human disease.
Conclusions and perspectives
Our study defines for the first time a unifying picture for ANKRD1 role in heart development, CHD and adult cardiomyopathy occurrence. The complexity and multifactorial components of human disease suggests a note of caution for any direct extrapolation from animal models to humans. Phenotypic variability of our Tg mice allows to speculate that fine modulation of interacting partners and signalling pathways could result in different disease outcome in humans, as previously proposed. 61 Our results open the perspective that gain of function mutations of ANKRD1 gene could be a prognostic early genetic marker for adult cardiomyopathy, in addition to congenital malformations, such as SV defects and TAPVR.
